Samsung Biologics, Samsung C&T extends investment in US biotech firms
The Life Science Fund, jointly launched by Samsung Biologics and Samsung C&T Corp., announced Wednesday it invested $15 million in US biotech fi...
SD Biosensor, SJL Partners to acquire Meridian Bioscience for $1.53 bn
SD Biosensor Inc., the world's largest COVID-19 test kit seller, and private equity firm SJL Partners LLC are jointly acquiring Meridian Bioscience ...
SK Bioscience wins marketing license for Korea's first COVID-19 vaccine
South Korea’s SK Bioscience Co., a biopharmaceutical unit of SK Group, has won marketing authorization for its COVID-19 vaccine from the Minis...
Korean drugmakers close to commercializing COVID-19 vaccine, pill
South Korea’s biopharmaceutical companies are close to commercializing a COVID-19 vaccine and treatment pill as they are on the brink of compl...
SK Bioscience seeks multi-billion-dollar M&As, eyes gene therapy sector
SK Bioscience Co., the biopharmaceutical unit of South Korea’s SK Group, is seeking multi-billion-dollar mergers and acquisitions to expand it...
SK Bioscience becomes first to win domestic COVID-19 vaccine contract
SK Bioscience Co. said it reached a deal with Korea’s disease control agency to supply 10 million doses of the country’s first experimen...
SK Bioscience posts record earnings driven by COVID-19 vaccines
SK Bioscience Co., a biopharmaceutical unit of South Korea’s SK Group, has posted record 2021 revenue and operating profit, boosted by contrac...
SK Bioscience to sell Novavax COVID-19 vaccine in Thailand, Vietnam
SK Bioscience Co., a biopharmaceutical unit of South Korea’s SK Group, said on Friday it has acquired non-exclusive rights to sell US-based No...
Activist fund again urges SK Chem to sell SK Bioscience stake
An activist fund has again urged South Korea’s SK Chemicals to sell part of its stake in SK Bioscience or buy back treasury shares and cancel ...
SK Chem says no immediate plan to sell SK Bioscience stake
SK Chemicals Co., the top shareholder of South Korea's SK Bioscience Co., is not considering reducing its stake in the vaccine maker in the immediat...
JW Bioscience in pancreatic cancer biomarker deal with Immunovia
JW Bioscience Co., a subsidiary of South Korea’s JW Life Science Co., has signed a non-exclusive agreement to transfer its patented technology...
Activist fund urges SK Chemicals to sell part of SK Bioscience stake
A Singaporean activist fund has urged South Korea’s SK Chemicals to sell some of its shares in SK Bioscience Co., saying its corporate value h...
MSCI adds SK Bioscience, SKIET, EcoPro BM to Korea Index
Global index provider Morgan Stanley Capital International (MSCI) added SK IE Technology Co. (SKIET), SK Bioscience Co. and EcoPro BM Co. to its K...
SK Bioscience to kick off phase 3 vaccine trials
SK Bioscience Co. has received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for phase 3 clinical trials of its COVID-19...
SK Bioscience secures up to $173.4 mn from CEPI for vaccine development
SK Bioscience Co. has secured additional funding for phase III clinical trial of GBP510, its COVID-19 vaccine candidate jointly developed with the I...
SK Bioscience halts flu vaccine output to focus on COVID vaccines
South Korea’s SK Bioscience Co. is suspending production of SKYCellflu, an influenza vaccine, to focus on manufacturing COVID-19 vaccines inst...
SK Bioscience debuts strong, up 160% from IPO price
SK Bioscience Co., a spin-off from the vaccine division of SK Chemicals, posted a strong debut on Kospi on Mar. 18, closing at 169,000 won a share, ...
SK Bioscience IPO draws record-high demand from retail investors
South Korean vaccine maker SK Bioscience Co. has set a new record for initial public offering demand, raising around 63.6 trillion won ($56 billio...
SK Bioscience’s $1.3 bn IPO generates $10 mn in underwriting fees
The initial public offering of SK Bioscience Co. was priced at the upper end of its price band of 65,000 won ($57.3) per share on Monday to raise 1....
SK Bioscience attracts NPS, GIC in successful bookbuilding
South Korea-based SK Bioscience Co. has successfully concluded the bookbuilding for its initial public offering, attracting institutional investors ...
SK Bioscience eyes $900 mn annual sales from vaccine business
South Korea’s SK Bioscience Co. is looking to post 1 trillion won ($900 million) in annual revenue from its vaccine business as the biopharmac...
Controversy surrounds SK Bioscience’s $1 bn IPO valuation
SK Bioscience Co., a spin-off of SK Chemicals Co.'s vaccine division, is set to list on the South Korean stock exchange on March 18 to raise up to $...
SK Bioscience aims for March listing; enterprise value may reach $4.5 bn
South Korea-based SK Bioscience Co. is planning its trading debut next month on the country's main bourse, Kospi. The company's enterprise value is ...
SK Bioscience begins listing process; enterprise value near $3 bn
South Korea’s SK Bioscience Co., set to enter clinical trials for its COVID-19 vaccine candidates, is expected to list on the Seoul main bours...
SK Bioscience wins COVID-19 vaccine manufacturing order from US firm
SK Bioscience Co. Ltd. has secured a contract manufacturing organization (CMO) order for a new coronavirus vaccine candidate under development by the ...
